anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: chemistry of polymers, pharmacy. SUBSTANCE: invention describes novel cascade polymeric complexes containing: a) complex-forming ligands of the general formula (I): A;X-[Y-(Z-(W-K w > z ) y ] x } a  where letters mean: A is nitrogen-containing cascade nucleus of basic multiplicity a; X and Y each means independently simple bond or repeated link in cascade of repeating multiplicity x, respectively y; Z and W each means independently repeated link in cascade of repeating multiplicity z, respectively w; K is residue of complex-forming agent; a is a number from 2 to 12; x, y, z and w each means independently numbers from 1 to 4 under condition that at least two repeated links are different and multiplicity product 16≅ a x y z w ≅ 64; b) at least 16 ions of element of ordinal numbers 57-83; c) if necessary cations of inorganic and/or organic bases, amino acids or amino acid amides and also d) if necessary acylated terminal amino-groups. New compounds are valuable compounds for diagnosis and therapy. They show good tolerance and high efficiency for recognition and localization of vessel diseases. Invention describes also the parent compounds and pharmaceutical composition for the above indicated prescription. EFFECT: new polymer complexes indicated above, valuable medicinal properties. 10 cl, 2 dwg, 1 tbl
FIELD: medicine.SUBSTANCE: invention relates to medicine, ophthalmology, traumatology, surgery, dentistry and cosmetology and can be used to urgently restore the natural color of the skin of the face under the eye in the presence of a hematoma that occurred during a soft tissue injury. In the convex part of the hematoma, two diametrically located and maximally distant areas are determined. One through elongated skin incision is performed therein, blood is exsanguinated by pressing the skin over the hematoma to the bone of the facial part of the skull. Head is given a position in which the cuts are vertically located one above the other, the head is fixed in the position and a solution of 3 % hydrogen peroxide and 10 % sodium bicarbonate at a temperature of 37–42 °C is injected through the lower incision in volume, ensuring bleaching of tissues. Upper incision is opened, ensuring the release of formed foam through it. After the hematoma bleaching is completed, the foam and inner fluids are released from its cavity by repeatedly pressing the skin against the bone of the facial part of the skull. Transparent, colorless aftershave gel is introduced into the hematoma cavity in a volume sufficient to cover the entire inner surface of the cavity with it. Sanitary napkin is applied to the skin over the hematoma, the skin is pressed against the bones of the facial part of the skull with open skin areas with incisions until the gel and gas bubbles stop flowing. Compress is applied to the hematoma area with a solution of 3 % hydrogen peroxide and 10 % sodium bicarbonate at a temperature of 37–42 °C for 10 min. Skin in the area of the hematoma is wiped with a damp cloth, smoothed to remove the remaining gas bubbles and dried. Incisions are glued with colorless skin glue, the skin in the area of the hematoma is covered with a foundation that has the complexion of the skin color.EFFECT: method provides emergency and traceless bleaching of skin hematomas under the eye in conditions that preclude local application of cold, development of cold spasm of blood vessels, feelings of pain, local hyperemia, drug dependence.1 cl, 1 ex
Participants with genotype F/F received TEZ/IVA FDC in the morning and IVA in the evening for 8 weeks. Participants with genotype F/RF received TEZ/IVA FDC and placebo matched to IVA in the morning and IVA in the evening for 8 weeks.
OBJECTIVE: To identify new genetic variants associated with SLE in Taiwan and establish polygenic risk score (PRS) models to improve the early diagnostic accuracy of SLE.
METHODS: The study enrolled 2429 patients with SLE and 48 580 controls from China Medical University Hospital in Taiwan. A genome-wide association study (GWAS) and PRS analyses of SLE and other three SLE markers, namely ANA, anti-double-stranded DNA antibody (dsDNA) and anti-Smith antibody (Sm), were conducted.
RESULTS: Genetic variants associated with SLE were identified through GWAS. Some novel genes, which have been previously reported, such as RCC1L and EGLN3, were revealed to be associated with SLE in Taiwan. Multiple PRS models were established, and optimal cut-off points for each PRS were determined using the Youden Index. Combining the PRSs for SLE, ANA, dsDNA and Sm yielded an area under the curve of 0.64 for the optimal cut-off points. An analysis of human leucocyte antigen (HLA) haplotypes in SLE indicated that individuals with HLA-DQA1*01:01 and HLA-DQB1*05:01 were at a higher risk of being classified into the SLE group.
CONCLUSIONS: The use of PRSs to predict SLE enables the identification of high-risk patients before abnormal laboratory data were obtained or symptoms were manifested. Our findings underscore the potential of using PRSs and GWAS in identifying SLE markers, offering promise for early diagnosis and prediction of SLE.
INTRODUCTION: Sexual health and wellbeing are significant aspects of quality of life. However, taking a sexual history is often avoided in medical practice, leaving a void in management and awareness. As the menopause can have a major impact on sexual health, it is imperative that healthcare providers are appropriately trained in sexual health and wellbeing and the aligned disciplines in order to achieve optimal care.
AIM: To provide an evidence-based clinical guide for the assessment and management of sexual problems at the menopause and beyond.
MATERIALS AND METHODS: Review of the literature and consensus of expert opinion.
RESULTS AND CONCLUSION: The assessment of sexual problems includes history taking, examination and laboratory investigation (if indicated), and occasionally the use of specific validated questionnaires. Management of sexual problems requires a multidimensional approach using biopsychosocial measures. Medical management and psychosexual counselling include pharmacological and non-pharmacological interventions, and sex therapy and psychoeducation. Furthermore, perimenopausal women should be advised about the need for contraception if they wish to avoid pregnancy. Also, sexually transmitted diseases can be acquired at any age. To conclude, taking a sexual history should be incorporated into medical practice and healthcare providers should be appropriately trained to assess and manage sexual problems at the menopause and beyond.
PURPOSE: To explore the impact of minimally invasive circumferential resection on inflammatory response and alveolar crest resorption in patients with dental defect implantation.
METHODS: A total of 198 patients who received dental implantation in Lishui Hospital of Traditional Chinese Medicine from June 2021 to June 2023 were selected and divided into minimally invasive group (n=100) and traditional group (n=98) according to treatment methods. Minimally invasive surgery was performed in the minimally invasive group and traditional flap surgery was performed in the traditional group.Surgical related indicators, levels of inflammatory factors, pain mediators, alveolar crest bone resorption, implant loosening, quality of life and complication rates were compared between the two groups. SPSS 27.0 software package was used for statistical analysis.
RESULTS: The surgery time, postoperative VAS scores and postoperative pain reaction time in the minimally invasive group were significantly lower than those in the traditional group(P<0.05). In the minimally invasive group, the concentrations of IL-8, TNF-α, INF-γ,serum amyloid A(SAA), substance P(SP), calcitonin gene-related peptide(CGRP) and 5-hydroxytryptamine(5-HT) were significantly lower than the traditional group (P<0.05). The amount of alveolar crest bone absorption in minimally invasive group was significantly lower than that in the traditional group(P<0.05). There was no significant differences in implant loosening and retention rates between the two groups(P>0.05). OHIP-14 scores across all dimensions in the minimally invasive group were significantly lower than in the traditional group (P<0.05). There was no significant difference in complication rate between the minimally invasive group and the traditional group (P<0.05).
CONCLUSIONS: Compared with the traditional surgery, minimally invasive circumferential surgery has better performance in reducing operation time, postoperative inflammatory factors and pain mediators, alveolar crest and parietal bone absorption and improving oral health, which can be widely used in dental implantation.
To investigate the effect of the Childbirth and Parenthood Preparation Education on Maternal Health Needs, Pregnancy-Related Anxiety and Fetal Health Anxiety in Primigravidas. A total of 148 pregnant women are planned to be included in the study. Data will be collected with the 'Pregnant Identification Form', 'Maternal Health Needs Scale', 'Pregnancy-Related Anxiety Scale-Revision 2' and 'Fetal Health Anxiety Inventory. The "Childbirth and Parenthood Preparation Education" program will be applied to the experimental group for a period of four weeks (a month (each week, once a week in total four sessions)). Within the scope of the "Childbirth and Parenthood Preparation training" program; Physiological and psychological changes in the mother during pregnancy, daily life during pregnancy, smoking, alcohol and substance use during pregnancy, exercise during pregnancy, nutrition and nutritional support during pregnancy, pregnancy follow-ups, routine examinations and immunization, common problems during pregnancy and suggestions for solutions, signs of danger during pregnancy and what to do, risky pregnancies, drug and human medicinal product management during pregnancy, labor process, drug-free methods for coping with labor pain, postpartum period and its characteristics, physiological changes in the mother after birth, psychological changes in puerperium, puerperal role and adaptation, postpartum behaviors , care of the newborn in the postpartum period, postpartum contraception methods will be explained. It is thought that the results of the research will contribute to the welfare of pregnant women by reducing maternal health needs, pregnancy-related anxiety and fetal health anxiety levels.
Participants will complete study assessments at the DC VAMC. Disease severity will be assessed by medical staff completing the EDSS. Peak torque assessment for the knee flexors and extensors will be performed on an isokinetic dynamometer (Biodex System 4). Muscle morphology measures of the rectus femoris will be obtained using diagnostic musculoskeletal B-mode ultrasound (Phillips EPIQ 7 180 Plus) with a 10 Mhz linear transducer. The sonographic measures will include muscle thickness and echogenicity. The mode of exercise testing and the type of muscle action will influence the assessment of fatigue. Therefore, isokinetic fatigue measures for the knee extensors will be assessed on separate visits (at least 48 hours apart). Performance-based measures of function will include an assessment of patient mobility and the 25-foot walk test. Muscle power will be estimated by the timed sit to stand test. Subjective measures of fatigue and quality of life include the MSQoL, MFIS, and Neurology Quality of Life Adult Fatigue Bank (AFB).
The present disclosure provides brush-poly(glycoamidoamine)-lipids (PGALs) ( e.g. , polymers of any one of Formulae (I)-(IV)) and methods of preparing the PGALs. A described PGAL may include poly(glycoamidoamine)-derived moieties ( e.g. , formula (AA) such as formula (BB) which may assist the PGAL and/or a complex of the PGAL and an agent to pass through cell membranes or be taken up by cells. Also provided are compositions including a described PGAL and an agent (e.g., polynucleotide, small molecule, peptide, or protein). The present disclosure also provides methods, kits, and uses that include or involve the PGALs or compositions for delivering an agent to a subject, tissue, or cell and/or for treating and/or preventing in a subject a range of diseases, such as genetic diseases, proliferative diseases, hematological diseases, neurological diseases, immunological diseases, gastrointestinal diseases, respiratory diseases, painful conditions, psychiatric disorders, musculoskeletal diseases, genitourinary diseases, and metabolic disorders.
The non-invasive high-intensity focused ultrasound has been coupled with high resolution MRI to provide precise, consistent treatments that can be monitored in real-time. The development of phased array transducers allows for tightly focused treatment volumes and for the ability to compensate for distortions by tissue inhomogeneities. The landmark advance in MRgFUS for neurosurgeons occurred as the ability to sonicate through the intact cranium was achieved with phased array transducers and acoustic modeling using CT reconstructions of the skull. By coupling HIFU with MRI, detailed treatment plans can be generated and intra-procedure real-time monitoring is available. Standard MR sequences have been shown to reliably predict tissue damage during thermal lesioning with ultrasound. The precision of the technology has already been demonstrated in animal models and is currently being investigated in humans with brain tumors and neuropathic pain syndromes. Unlike stereotactic radiosurgery, the treatment can be monitored continuously in real time with MRI and MR-thermography. We anticipate that a MRgFUS non-invasive thermal lesioning is similarly as safe as DBS (or other current procedure and will provide several years of benefit through reduction of contralateral motor symptoms and potential medication side effects in ET, while still permitting subsequent treatment with DBS should that become clinically desirable.
The design of this translation trial is a single-center, single cohort, open-label and non-masked study. The aim is to evaluate tolerability of chronic low-frequency electrical stimulation of the VMH, while achieving weight loss in morbidly obese subjects. The subjects must have a body-mass index \[BMI\] greater than 40, and no obesity co-morbidities, such as diabetes or cardiopulmonary abnormalities. Up to six subjects will be implanted in this protocol.
NEW MATERIAL:A peptide (salt) expressed by the formula (Y represents S or methylene; A represents Asn or Asp). USE:A remedy for calcium dysbolism, malum cordis, ulcer, etc. and an ameliorating agent for brain circulation. PREPARATION:For example, three amino acids of 1st-3rd amino acids counted from C-terminus are condensed successively onto benzhydrylamine resin according to aminoacid sequence of a peptide. In the reaction, condensation is carried out after protecting amino groups and side-chain functional groups of the amino acid and in the presence of a condensing agent, etc. Then, after removing the amino-protecting group, a next functional group-protected amino acid is bound. By repeating this procedure, the resin on which a peptide fragment of 3rd-37th amino acids is bound is obtained. Then the terminus thereof is acylated with beta-mercaptopropionic acid and both protecting groups and the resin are removed therefrom by one step reaction with an anhydrous hydrogen fluoride, etc., and free mercapto groups thereof are intramolecularly disulfided to afford the peptide expressed by the formula.
PURPOSE: An anti-cancer composition containing Psidium cattleianum Sabine leaf extract is provided to induce apoptosis of cancer cells and to ensure anti-proliferative activity of cancer cells. CONSTITUTION: An anti-cancer composition contains Psidium cattleianum Sabine leaf extract as an active ingredient. The extract is isolated using water, anhydrous or hydrous low alcohol of 1-4 carbon atoms, acetone, ethyl acetate, butyl acetate, or 1,3-butylene glycol. The composition is a pharmaceutical composition for preventing or treating cancer or a functional food composition for treating or relieving cancer. The daily dose of the pharmaceutical composition is 0.001-1000 mg/kg(body weight). The pharmaceutical composition is taken by oral or parenteral administration.
Subjects will receive e-cigarettes for a total of 4 weeks. A mobile contingency management (mCM) procedure will be used to provide monetary reinforcement for biochemically verified abstinence from combustible cigarettes. After 4 weeks, subjects will be allowed to transition back to their chosen combustible cigarette product for an additional 2 weeks. Respiratory assessments will occur at study arm assignment (Visit 1) to establish baseline measures of lung function, oxidative stress, and systemic inflammation, repeated again 4 weeks after transition to ECIG (Visit 4) and again 2 weeks after stopping ECIG (Visit 5). Neuro-cognitive and behavioral assessments will occur at Visits 2, 3, 4 and 5.
Bacterial and fungal superinfections are common in COVID-19, and early diagnosis can enable timely intervention. Serum calprotectin levels increase with bacterial, fungal, and viral infections. This study evaluated serum calprotectin as a diagnostic and prognostic tool for microbial superinfections in COVID-19. Serum samples from adult patients with moderate and severe COVID-19 were collected during hospitalization from 2020 to 2024. Calprotectin levels were measured using an enzyme-linked immunosorbent assay in 63 patients with moderate COVID-19, 60 patients with severe COVID-19, and 34 healthy individuals. Calprotectin serum levels were elevated in patients with moderate COVID-19 compared with controls, and these levels were further increased in the severe cases. Patients with severe COVID-19 and vancomycin-resistant enterococci (VRE) bacteremia had elevated calprotectin levels, but their C-reactive protein and procalcitonin levels were not increased. Fungal superinfections and herpes simplex virus reactivation did not change the calprotectin levels. A calprotectin concentration of 31.29 µg/mL can be used to diagnose VRE bloodstream infection with 60% sensitivity and 96% specificity. These data suggest that serum calprotectin may be a promising biomarker for the early detection of VRE bloodstream infections in patients with COVID-19.
The invention relates to a novel oral capsule preparation for treating cancer and AIDS. The technical scheme is achieved as follows: the capsule preparation adopts a double-layer capsule structure which is sequentially provided with a medicine layer, a water-soluble capsule and an enteric capsule from inside to outside. The novel oral capsule preparation comprises the following components according to the weight per unit: 5-50mg of protein medicine, 20-150mg of assistant absorbent and 300-600mg of protease inhibitor. The protein medicine is interleukin 2. The assistant absorbent is bezoar deoxycholic acid or lauryl novain. The protease inhibitor is citric acid. The preparation method comprises the following steps: uniformly mixing the protein medicine, the enteric canal assistant absorbent and the protease inhibitor according to a certain proportion; encapsuling the water-soluble capsule in mixture, and then applying the enteric capsule. The invention solves the problem of low absorption rate of the protein medicine, releases the problem that the protein oral medicine is degraded by the protease in the enteric canal and increases the absorption rate of the protein medicine in the enteric canal so as to lead the interleukin 2 oral medicine to be capable of achieving the treatment concentration in the human body.
In this study, stratified block randomization was employed for random grouping, and the total sample size required as calculated was 410 individuals. Firstly, 410 subjects were assigned ID numbers ranging from 1 to 410. SPSS.26 statistical software was utilized to apply the "random number generator" by setting the "fixed seed number" to "20231121", and subsequently generate random numbers. Once the random numbers were obtained, random sampling and grouping were conducted. This study was a multicenter trial, with block randomization stratified by center. The total sample size of 410 was distributed across 4 cities, and the samples collected in each city were randomly allocated into 5 treatment groups (groups A, B, C, D, and E), with approximately 20 individuals in each group.
BACKGROUND: Invasive fungal infections (IFIs) are severe and difficult-to-treat infections affecting immunocompromised patients. Antifungal drug penetration at the site of infection is critical for outcome and may be difficult to achieve. Data about antifungal drug distribution in infected human tissues under real circumstances of IFI are scarce.
METHODS: Multiple samples were obtained from soft tissue abscesses of a lung transplant patient with Candida albicans invasive candidiasis who underwent recurrent procedures of drainage, while receiving different consecutive courses of antifungal therapy [itraconazole (ITC), fluconazole, caspofungin]. Antifungal drug concentrations were measured simultaneously at the site of infection (surrounding inflammatory tissue and fluid content of the abscess) and in plasma for calculation of the tissue/plasma ratio (R). The concentration within the infected tissue was interpreted as appropriate if it was equal or superior to the MIC of the causal pathogen.
RESULTS: A total of 30 tissue samples were collected for measurements of ITC (n = 12), fluconazole (n = 17) and caspofungin (n = 1). Variable concentrations were observed in the surrounding tissue of the lesions with median R of 2.79 (range 0.51-15.9) for ITC and 0.94 (0.21-1.37) for fluconazole. Concentrations ranges within the fluid content of the abscesses were 0.39-1.83 for ITC, 0.66-1.02 for fluconazole and 0.23 (single value) for caspofungin. The pharmacodynamic target (tissue concentration ≥ MIC) was achieved in all samples for all three antifungal drugs.
CONCLUSIONS: This unique dataset of antifungal drug penetration in infected human soft tissue abscesses suggests that ITC, fluconazole and caspofungin could achieve appropriate concentrations in soft tissue abscesses.
The present invention provides a pharmaceutical composition that has excellent safety and targets a different step in the virus propagation cycle than conventional pharmaceutical compositions, applicable as an antiviral agent. A pharmaceutical composition containing an epigallocatechin gallate derivative represented by the following chemical formula (1), an isomer thereof, or a salt thereof is prepared. This can be used as a membrane fusion inhibitor that inhibits viral membrane fusion. In the following formula, R 1  to R 6  are each a hydrogen atom, halogen, sodium, potassium, or a straight-chain or branched, saturated or unsaturated acyl group and may be identical to or different from one another. The acyl group may be substituted further with one or more substituents. At least one of R 1  to R 6  is the acyl group. R 7  to R 16  are each a hydrogen atom, halogen, sodium, or potassium and may be identical to or different from one another.
The first 9 patients will receive the PEEK prosthesis (PP) first. After 3 months, chewing efficiency, maximum bite force, patient satisfaction, and OHRQoL will be measured, and PP will be replaced by a Titanium prosthesis (TP). After another 3 months, the measurements will be repeated.